These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
31. Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy. Hay KA; Gauthier J; Hirayama AV; Voutsinas JM; Wu Q; Li D; Gooley TA; Cherian S; Chen X; Pender BS; Hawkins RM; Vakil A; Steinmetz RN; Schoch G; Chapuis AG; Till BG; Kiem HP; Ramos JD; Shadman M; Cassaday RD; Acharya UH; Riddell SR; Maloney DG; Turtle CJ Blood; 2019 Apr; 133(15):1652-1663. PubMed ID: 30728140 [TBL] [Abstract][Full Text] [Related]
32. Selinexor Combined with Ibrutinib Demonstrates Tolerability and Safety in Advanced B-Cell Malignancies: A Phase I Study. Stephens DM; Huang Y; Ruppert AS; Walker JS; Canfield D; Cempre CB; Fu Q; Baker S; Hu B; Shah H; Vadeboncoeur R; Rogers KA; Bhat S; Jaglowski SM; Lockman H; Lapalombella R; Byrd JC; Woyach JA Clin Cancer Res; 2022 Aug; 28(15):3242-3247. PubMed ID: 35608822 [TBL] [Abstract][Full Text] [Related]
33. Preclinical evaluation of combination nemtabrutinib and venetoclax in chronic lymphocytic leukemia. Muhowski EM; Ravikrishnan J; Gordon B; Yu L; Misra S; Walker B; Eathiraj S; Sampath D; Rogers KA; Byrd JC; Woyach JA J Hematol Oncol; 2022 Nov; 15(1):166. PubMed ID: 36380319 [TBL] [Abstract][Full Text] [Related]
34. The safety of Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia. Tran PN; O'Brien S Expert Opin Drug Saf; 2017 Sep; 16(9):1079-1088. PubMed ID: 28627951 [TBL] [Abstract][Full Text] [Related]
35. Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL. Siddiqi T; Soumerai JD; Dorritie KA; Stephens DM; Riedell PA; Arnason J; Kipps TJ; Gillenwater HH; Gong L; Yang L; Ogasawara K; Thorpe J; Wierda WG Blood; 2022 Mar; 139(12):1794-1806. PubMed ID: 34699592 [TBL] [Abstract][Full Text] [Related]
36. Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase II Study of an MRD-Driven Approach. Roeker LE; Feldman TA; Soumerai JD; Falco V; Panton G; Dorsey C; Zelenetz AD; Falchi L; Park JH; Straus DJ; Pena Velasquez C; Lebowitz S; Fox Y; Battiato K; Laudati C; Thompson MC; McCarthy E; Kdiry S; Martignetti R; Turpuseema T; Purdom M; Paskalis D; Miskin HP; Sportelli P; Leslie LA; Mato AR Clin Cancer Res; 2022 Sep; 28(18):3958-3964. PubMed ID: 35852793 [TBL] [Abstract][Full Text] [Related]
37. Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies. Aw A; Brown JR Drugs Aging; 2017 Jul; 34(7):509-527. PubMed ID: 28536906 [TBL] [Abstract][Full Text] [Related]
38. Humanized Anti-CD19 CAR-T Cell Therapy and Sequential Allogeneic Hematopoietic Stem Cell Transplantation Achieved Long-Term Survival in Refractory and Relapsed B Lymphocytic Leukemia: A Retrospective Study of CAR-T Cell Therapy. Chen W; Ma Y; Shen Z; Chen H; Ma R; Yan D; Shi M; Wang X; Song X; Sun C; Cao J; Cheng H; Zhu F; Sun H; Li D; Li Z; Zheng J; Xu K; Sang W Front Immunol; 2021; 12():755549. PubMed ID: 34777367 [TBL] [Abstract][Full Text] [Related]
39. Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial. Farooqui MZ; Valdez J; Martyr S; Aue G; Saba N; Niemann CU; Herman SE; Tian X; Marti G; Soto S; Hughes TE; Jones J; Lipsky A; Pittaluga S; Stetler-Stevenson M; Yuan C; Lee YS; Pedersen LB; Geisler CH; Calvo KR; Arthur DC; Maric I; Childs R; Young NS; Wiestner A Lancet Oncol; 2015 Feb; 16(2):169-76. PubMed ID: 25555420 [TBL] [Abstract][Full Text] [Related]